News | Women's Health | August 20, 2019

Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy

New study suggests ways to enhance pregnancy screening measures to limit fetal exposure to controversial contrast agent

Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy

August 20, 2019 — A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent early in their pregnancy, likely before many of them are aware that they are pregnant, according to a study published in the journal Radiology.1 The results support adherence to effective pregnancy screening measures to help reduce inadvertent exposures to these contrast agents during early pregnancy.

Gadolinium-based contrast agents (GBCAs) are used in as many as 45 percent of MRI exams in the United States to improve the visualization of organs and tissue. Recent evidence shows that trace levels of gadolinium may be retained in the body after the MRI, although the implications of this are not yet understood.

Gadolinium can cross the placenta and enter the fetal circulation. The safety of GBCAs in pregnant women has not been established, and their use during pregnancy is not recommended unless essential to the health of the woman or fetus. Available data from cohort studies and case reports have revealed inconsistent findings regarding the association between gadolinium and adverse fetal outcomes.

To obtain a more precise idea of the prevalence of GBCA exposure among pregnant women, study lead author Steven Bird, Pharm.D., Ph.D., of the U.S. Food and Drug Administration’s (FDA) Division of Epidemiology, and colleagues analyzed data on U.S. pregnancies resulting in live births between 2006 and 2017. The data was collected from 16 partners of the FDA’s Sentinel System, a program that allows for active surveillance of healthcare data from multiple sources to monitor the safety of regulated medical products.

The data revealed exposures to GBCAs in 5,457 of 4,692,744 live births, a number corresponding to one in 860 pregnancies. Most of the exposures came from contrast MRI examinations of the head, although the number of pelvic and abdominal MRIs were also noteworthy. Almost three-quarters of exposures occurred during the first trimester. The results strongly suggested that inadvertent exposure to GBCAs may occur before pregnancy is recognized.

“Unintended fetal exposures to gadolinium can occur during early pregnancy among women who are not yet aware they are pregnant. Increased attention to existing pregnancy screening measures may help reduce inadvertent exposures to gadolinium contrast,” Bird said.

The FDA has advised all MRI centers to provide a medication guide to outpatients during their first gadolinium contrast administration, stating that pregnant women and young children may be at increased risk from gadolinium staying in the body.

The researchers suggested several ways radiology imaging centers might avoid inadvertent administration of GBCAs to pregnant women. Among the tools are: 

  • A safety screening form asking about the potential for pregnancy; 
  • Direct questioning of women by radiologic technologists regarding pregnancy; 
  • Prominently displayed signs asking women to notify radiology staff if they may be pregnant; and 
  • Pregnancy testing when appropriate.

The FDA is continuing to monitor reports of adverse events associated with gadolinium exposure in utero. While this study was not designed to assess health outcomes of this early exposure for women and/or infants, the FDA is collaborating on and funding a study to evaluate potential risk for stillbirth and other neonatal adverse effects following in utero exposure to gadolinium in a large group of pregnant Medicaid beneficiaries.

For more information: www.pubs.rsna.org/journal/radiology

 

Reference 

1. Bird S.T., Gelperin K., Sahin L., et al. First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S. Pregnancies. Radiology, published online Aug. 20, 2019. https://doi.org/10.1148/radiol.2019190563

Related Content

Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
Sponsored Content | Videos | Flat Panel Displays | February 19, 2020
EIZO medical monitors were showcased recently at RSN...
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Hyperfine Research, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system

Hyperfine's point-of-care MRI wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet. Photo courtesy of Business Wire

News | Magnetic Resonance Imaging (MRI) | February 12, 2020
February 12, 2020 — Hyperfine Research, Inc. announced that i
The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly

Image courtesy of GE Healthcare

News | Magnetic Resonance Imaging (MRI) | February 11, 2020
February 11, 2020 — The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly in the fo
CT image of Novel Coronavirus 2019-nCoV from the Radiology article showing a baseline CT image of a 75 year old male with multiple patchy areas of pure ground glass opacity (GGO) and GGO with reticular and/or interlobular septal thickening. Follow-up CT images on day 3 after admission show an overlap of organizing pneumonia with diffuse alveolar damage in that it is more diffuse and associated with underlying reticulation. Read more and see 15 more images from novel coronavirus patients in the article.

An image from the Radiology article showing a baseline CT image of a 75 year old male with multiple patchy areas of pure ground glass opacity (GGO) and GGO with reticular and/or interlobular septal thickening. Follow-up CT images on day 3 after admission show an overlap of organizing pneumonia with diffuse alveolar damage in that it is more diffuse and associated with underlying reticulation. Read more and see 15 more images from novel coronavirus patients in the article.

Feature | Computed Tomography (CT) | February 11, 2020
February 11, 2020 — The Radiological Society of North America (RSNA) jo
PaxeraHealth enterprise imaging, PACS, VNA solutions
News | Enterprise Imaging | February 11, 2020
February 11, 2020 — Enterprise Imaging developer PaxeraHealth
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...